Emissary Contract Research Organization Featured Articles

The Historical Rise of Pharmaceutical Regulation

Sun, 01 Jan 1995 06:00:00 +0000

The first rumblings for US drug legislation began after the Civil War, which had spurred the separation of drug manufacturers from drug prescribers and drug dispensers. This was the time of the traveling medicine shows selling dangerous, addictive or just non-sense patent medicines. Today's pharmaceutical companies got their start in the apothecary shops of that time, but still, most drugs were imported from Europe. In fact the U.S was a dumping ground for substandard and contaminated drugs.

Time Management for the Research Professional

Mon, 01 Jan 1996 16:25:51 +0000

It's been said that a pharmaceutical company loses $1 million for every day of delay during clinical research and development. This is a theoretical cost related to the dramatic reduction in sales when a drug product loses patent protection and becomes subject to generic competition. Nevertheless, the fact remains that, as clinical research professionals, we must be excellent managers, not just of others, but of our own time, as well.

Consulting is an Art

Wed, 01 Jul 1998 06:00:00 +0000

...or Why I'm Not a Singing CRA

During those confusing and wondrous years, when a young man ponders his career choices, my dream was to become a singer-songwriter. Blowing my hard-earned profits from an after school job on a multi-track recorder, I spent precious study time mixing down vocal, guitar and synthesizer tracks composing what would surely become the next big platinum album.

Clinical Research Regulation: FDA vs. ICH

Sat, 02 Jan 1999 17:28:50 +0000

On May 9th, 1997, the US Food and Drug Administration (FDA) published in the FEDERAL REGISTER (vol. 62, No 90), the latest rendition of the International Conference on Harmonization (ICH) Guideline covering the conduct of clinical research studies in the seven member nations. Guidelines represent the agency's current thinking on Good Clinical Practices, but do not bind the FDA or the public. However, most clinical research studies are now being conducted in compliance with this guideline, especially if the results might be used for an international regulatory submission. Here are the major differences.

Clinical Trial Outsourcing Emerging as a Key Trend in Drug Research And Development Markets

Sun, 23 Dec 2001 04:24:54 +0000

Preview

TORONTO, Nov. 12 /PRNewswire/ --

Contract research organizations (CROs) are a growing trend among the pharmaceutical and biotechnology sectors as these companies look to reduce the costs of drug development. However, there are tradeoffs between the size of a CRO and the therapeutic and local expertise dedicated to individual projects.

Emissary Technology Key to Enrolling First Patient Within 7 Days of FDA Approval of a Dialysis Graft Trial

Fri, 19 Jul 2002 05:12:10 +0000

Emissary Inc. has been selected by Novoste Corporation (Nasdaq:NOVT) to collaborate on monitoring and clinical trial management of Novoste's BRAVO (Beta Radiation for treatment of Arterial-Venous graft Outflow) clinical trial.

Physicians find clinical research brings income and treatment options

Fri, 02 Aug 2002 05:01:15 +0000

Preview

Trying their patients: practitioners find clinical research projects, chosen well, can create extra income and widen treatment options.

Phase III clinical research has the potential for eye-catching margins, but private practitioners who enter the, field with that motive seldom stay. The reason? Financial returns don't come easily, and the process is fraught with opportunities for failure.

Emissary Presents at Southwest Equity Capital Summit

Thu, 03 Oct 2002 04:32:56 +0000

AUSTIN, Texas -- Emissary Inc. today announced that it will participate in the 2002 Southwest Equity Capital Summit organized by the Capital Network October 2-3 in Richardson, Texas. Steven Mayo, founder and CEO of Emissary, will present the company's plans to streamline drug and medical device research studies with a new Web-based software initiative.

Clinical Trial Accrual Hampered by Many Factors

Fri, 04 Oct 2002 06:00:00 +0000

In recent years, cancer patients are more knowledgeable and willing to participate in clinical trials, but issues pertaining to physician enthusiasm, design requirements, and enrollment procedures now pose large barriers to patient accrual, finds two new Cancer studies. Since previous research has predominantly focused on patient and physician perspectives, Canadian researchers interviewed clinical research associates (CRAs), whose work spans all stages of clinical trials, to gain new insight into the factors influencing enrollment. The CEO of an Austin, Texas-based contract research organization (CRO), which designs trials and staffs CRAs, told the Watch (9/24/02) that the strict participation guidelines for oncology-related clinical trials make meeting accrual goals for experimental cancer therapies particularly difficult.

Emissary Launches TeamTrials Clinical Research Platform for Electronic Data Capture (EDC)

Wed, 23 Oct 2002 04:47:24 +0000

AUSTIN, Texas--(BUSINESS WIRE)--Oct. 22, 2002

Contract clinical research organization Emissary Inc. today introduced TeamTrials, a comprehensive Web-based software platform for conducting clinical trials.

Emissary is using TeamTrials to streamline its customers' research studies, enabling faster, more efficient trials for new medical devices, drugs, biopharmaceuticals and other life-improving medical products.